| 0.7091 0.076 (11.95%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.07 | 1-year : | 1.25 |
| Resists | First : | 0.92 | Second : | 1.07 |
| Pivot price | 0.63  |
|||
| Supports | First : | 0.55 | Second : | 0.33 |
| MAs | MA(5) : | 0.63 |
MA(20) : | 0.6 |
| MA(100) : | 0.68 |
MA(250) : | 0.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.8 |
D(3) : | 38.6 |
| RSI | RSI(14): 58.4 |
|||
| 52-week | High : | 1.79 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FEMY ] has closed below upper band by 20.3%. Bollinger Bands are 12.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.76 |
| Low: | 0.62 - 0.62 | 0.62 - 0.62 |
| Close: | 0.7 - 0.71 | 0.71 - 0.71 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Wed, 22 Oct 2025
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe - GlobeNewswire
Wed, 22 Oct 2025
Femasys (NASDAQ: FEMY) starts FemBloc post-market study under EU MDR and ethics approvals - Stock Titan
Thu, 16 Oct 2025
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - Stock Titan
Thu, 16 Oct 2025
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - Yahoo Finance
Thu, 25 Sep 2025
First Non-Surgical Permanent Birth Control: Femasys' FemBloc Launches Major European Expansion - Stock Titan
Thu, 25 Sep 2025
Femasys Inc. Partners with Kebomed to Expand FemBloc Permanent Birth Control Availability in France and Benelux Region - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 43 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 14.1 (%) |
| Shares Short | 3,490 (K) |
| Shares Short P.Month | 1,230 (K) |
| EPS | -0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | -941.1 % |
| Return on Assets (ttm) | -70.4 % |
| Return on Equity (ttm) | -329.5 % |
| Qtrly Rev. Growth | 84.8 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | 14.18 |
| Price to Sales | 16.13 |
| Price to Cash Flow | -1.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|